PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of asnneuroAboutEditorial BoardInfo for AuthorsSubmissionASN NEUROASN NEURO
 
ASN Neuro. 2011; 3(3): e00060.
Published online 2011 June 7. Prepublished online 2011 May 4. doi:  10.1042/AN20110009
PMCID: PMC3155197

Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function

Abstract

HD (Huntington's disease) is characterized by dysfunction and death of striatal MSNs (medium-sized spiny neurons). Excitotoxicity, transcriptional dysregulation and mitochondrial abnormalities are among the mechanisms that are proposed to play roles in HD pathogenesis. To determine the extent of cell-autonomous effects of mhtt (mutant huntingtin) protein on vulnerability to excitotoxic insult in MSNs in vivo, we measured the number of degenerating neurons in response to intrastriatal injection of QA (quinolinic acid) in presymptomatic and symptomatic transgenic (D9-N171-98Q, also known as DE5) mice that express mhtt in MSNs but not in cortex. After QA, the number of degenerating neurons in presymptomatic DE5 mice was not significantly different from the number in WT (wild-type) controls, suggesting the early, increased vulnerability to excitotoxicity demonstrated in other HD mouse models has a largely non-cell-autonomous component. Conversely, symptomatic DE5 mice showed significantly fewer degenerating neurons relative to WT, implying the resistance to excitotoxicity observed at later ages has a primarily cell-autonomous origin. Interestingly, mitochondrial complex II respiration was enhanced in striatum of symptomatic mice, whereas it was reduced in presymptomatic mice, both relative to their age-matched controls. Consistent with the QA data, MSNs from symptomatic mice showed decreased NMDA (N-methyl-d-aspartate) currents compared with age-matched controls, suggesting that in addition to aging, cell-autonomous mechanisms mitigate susceptibility to excitotoxicity in the symptomatic stage. Also, symptomatic DE5 mice did not display some of the electrophysiological alterations present in other HD models, suggesting that blocking the expression of mhtt in cortical neurons may restore corticostriatal function in HD.

Keywords: complex II, excitotoxicity, Huntington's disease (HD), mitochondria, N-methyl-d-aspartate (NMDA), striatum
Abbreviations: ACSF, artificial cerebrospinal fluid; EPSC, excitatory postsynaptic current; FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone; FJC, Fluoro-Jade C; GABAA, γ-aminobutyric acid type A; HD, Huntington's disease; htt, huntingtin; IP, intraperitoneally; IPSC, inhibitory postsynaptic current; mEPSC, miniature EPSC; mhtt, mutant htt; MSN, medium-sized spiny neuron; NMDA, N-methyl-d-aspartate; NMDAR, NMDA receptor; PGC-1α, peroxisome-proliferator-activated receptor γ co-activator-1α; QA, quinolinic acid; sEPSC, spontaneous EPSC; sIPSC, spontaneous IPSC; TMPD, N,N,N′,N′-tetramethylphenylenediamine; TTX, tetrodotoxin; WT, wild-type

INTRODUCTION

HD (Huntington's disease) is an autosomal-dominant, fatal neurodegenerative disorder characterized by progressive deterioration of cognitive and motor functions. The pathological mutation in the HD gene htt (huntingtin) is the expansion of a polymorphic CAG (glutamine) repeat to >36, with a longer repeat length being associated with earlier onset and more severe disease progression (Cowan and Raymond, 2006). The functions of normal htt have not been entirely delineated, but it is found in the cytoplasm, soma, dendrites and synaptic terminals of neurons. Htt is necessary for proper mitotic spindle orientation (Godin et al., 2010) and also associates with transcription factors, mitochondria, vesicular membranes and transport machinery. Its association with diverse cellular processes suggests vital functional roles and the mouse htt–null mutation is lethal (Duyao et al., 1995; MacDonald et al., 1996). The mutation in HD may lead to increased oxidative stress, impaired energy metabolism and abnormal interactions with other proteins, which in some cases lead to dysregulation of transcriptional machinery and altered gene expression (Cowan and Raymond, 2006; Zhou and Baudry, 2006; Fan and Raymond, 2007; Brown et al., 2008; Nicholls, 2009). Although mhtt (mutant htt) is ubiquitously expressed and present in all regions and cell types of the brain, striatal GABAergic MSNs (medium-sized spiny neurons) are particularly vulnerable. Other regions, particularly neocortex, are also affected (Vonsattel et al., 1985; Cowan and Raymond, 2006). A challenging issue in the study of HD remains the delineation of mechanisms of neuronal subtype vulnerability.

The ‘excitotoxicity hypothesis’ of neurodegeneration was first proposed in 1957 (Lucas and Newhouse, 1957) and it persists as a likely pathophysiological mechanism in HD. Excitotoxicity refers to the phenomenon in which overactivated ionotropic glutamate receptors respond to excitatory neurotransmitters via a pathway that leads to neuronal damage. Rapid and prolonged influx of calcium and/or dysregulation of intracellular calcium appear critical to the initiation of degeneration (Collingridge and Lester, 1989; Coyle and Puttfarcken, 1993; Cowan and Raymond, 2006; Zhou and Baudry, 2006; Hardingham, 2009).

Before the creation of transgenic mouse models of HD, chemical insults to the striatum served as useful disease models. Early HD models that recapitulated the behavioural and neuropathological features of HD included intrastriatal injection of NMDAR [NMDA (N-methyl-d-aspartate) receptor] agonists, for example QA (quinolinic acid) (DiFiglia, 1990; Guidetti et al., 2004; Sapko et al., 2006; Graham et al., 2009), or injection of an inhibitor of mitochondrial succinate dehydrogenase, 3-nitropropionic acid (Brouillet et al., 1995). The role of excitotoxicity in HD pathophysiology has been investigated in at least six commonly utilized pan-cellular and pan-neuronal HD mouse models (Nicholls, 2009).

In order to examine the contribution of intrinsic, cell-autonomous vulnerability of MSNs to excitotoxicity, we measured the number of degenerating neurons after injecting QA in the striatum of presymptomatic and symptomatic D9-N171-98Q, also known as DE5, transgenic mice (Brown et al., 2008) that, within the forebrain, selectively express mhtt in the MSNs, excluding neocortical and glial expression. Thus, we define ‘cell-autonomous’ as alterations that occur in MSNs independent of transgene expression in neocortical and striatal interneurons and in glia. Non-cell-autonomous factors include those that require transgene expression in cells other than MSNs, for example, excessive glutamate release and decreased neurotrophic support due to abnormalities of cortical neurons (Altar et al., 1997; Cepeda et al., 2007). Such anatomical interdependence compounds the difficulty in assessment of the relative contribution of each region to HD pathogenesis (Gu et al., 2007; Brown et al., 2008). We also examined mitochondrial function and electrophysiological properties of MSNs in the striatum of this model, as abnormalities of both are known to change sensitivity to excitotoxic insult.

MATERIALS AND METHODS

Animals

The creation and characterization of the mice used have been previously described (Brown et al., 2008). Transgenic DE5 mice expressing the first 171 amino acids of htt with 98 CAG repeats (D9-N171-98Q) and their WT (wild-type) littermates were used in this study. This transgenic line was produced, and has remained, on a C57Bl6/J background. Mice were group-housed (4–5/cage) on a 12 h light/12 h dark. Water and food were available ad libitum. Mice were either 2–3 or >14 months old at the time of their surgeries. A total of 33 mice received intrastriatal QA injections. The animal protocol was approved by the IACUC of Mount Sinai School of Medicine.

Surgery

QA was dissolved in 0.1 M PBS (pH 7.4). Under pentobarbital anesthesia [50 mg/kg IP (intraperitoneally)], the mice received a unilateral intrastriatal injection of 15 nmol of QA in 1 μl at the following stereotaxic coordinates using a 2.5 μl Hamilton syringe: 0.05 cm rostral to Bregma, 0.2 cm to the right of the midline and 0.3 cm ventral to the dural surface, with the bar set to zero. The injection rate was 0.5 μl/min, and the needle was left in place for an additional 3 min before slowly retracting it to prevent retrograde leakage.

Fluoro-Jade staining

FJC (Fluoro-Jade C; Millipore) stains degenerating neurons in the brain (Schmued et al., 1997). FJC was performed as described in the manufacturer's instruction (Millipore) with some modifications. Briefly, perfusion-fixed brain sections were mounted, dried and immersed in 90% ethanol, followed by basic alcohol solution (1% NaOH in 80% alcohol) for 5 min, followed by 70, 60, 50, 40, 30, 20 and 10% ethanol and Milli-Q water incubation, for 2 min each. Sections were treated with 0.06% KMnO4 for 10 min. After rinsing in water, sections were immersed in FJC (0.0001% FJC in 0.1% acetic acid) for 10 min in the dark.

Histology

Three days after intrastriatal QA injection, mice were perfused with 4% (w/v) paraformaldehyde in PBS under pentobarbital anesthesia (50 mg/kg IP). The brains were post-fixed overnight in the same solution at 4°C, dehydrated in 30% sucrose/0.1 M PBS, and then mounted using Tissue-TEK O.C.T. compound (Sakura). Mouse brains were cut using a cryostat (Leica CM3050) and every fifth serial coronal section (30 μm) was stained with FJC.

Stereology

For assessment of the number of FJ-positive cells, a 25×25 μm counting frame was randomly placed within the delineated striatal area and then systematically moved through the tissue. The number of FJ-positive cells was then determined by StereoInvestigator software (Microbrightfield). The striatum for each section was delineated rostral-caudal with the anterior commissure marking the caudal boundary of sampling using StereoInvestigator software. Striatal volume was also assessed using the Cavalieri principle (Gundersen and Jensen, 1987).

Mitochondrial respiration assay

After mice were killed without agents that compromise mitochondrial function, brains were quickly removed and striata were isolated in an ice-cold dissection buffer (50 mM Hepes, pH 7.5, 125 mM NaCl, 100 mM sucrose and 2 mM KCl). Striata from two mice of each genotype were pooled for mitochondrial isolation for complex I assay, and striata from one mouse each for complex II and IV assays. Tissue samples were homogenized in 8 ml (complex I) or 4 ml (complexes II and IV) of homogenizing buffer (320 mM sucrose, 5 mM Tris, 2 mM EGTA, final pH 7.4, 4°C) with a Teflon-glass Potter–Elvehjem homogenizer. Samples were centrifuged for 3 min at 2000 g to remove nuclei and tissue particles. Supernatants were collected and centrifuged for 10 min at 12000 g to pellet mitochondria and synaptosomes. The crude pellet was resuspended in 3 ml of the homogenizing buffer with the addition of 0.02% (w/v) digitonin to disrupt synaptosomal membranes and release mitochondria. The resuspended pellet was centrifuged for 10 min at 12000 g to pellet mitochondria, which was resuspended in 30 μl of mitochondria respiration media (70 mM sucrose, 220 mM mannitol, 2 mM Hepes buffer, 5 mM MgCl2, 5 mM KHPO4, 1 mM EDTA and 0.1% fatty acid free BSA, pH 7.4), and protein content was determined by BCA (bicinchoninic acid) assay (Sigma). Isolated mitochondria were resuspended in 2.5 ml mitochondria respiration medium and assayed for state 4 respiration using 8 mM glutamate/8 mM malate (complex I), 4 mM succinate (complex II) or 0.24 mM TMPD (N,N,N′,N′-tetramethylphenylenediamine)/2 mM ascorbate (complex IV). ADP was added (40 μM for complex I and 100 μM for complex II) to induce state 3 respiration. After ADP was depleted and respiration returned to state 4, FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone), a potent uncoupler of oxidative phosphorylation, was added to the reaction chamber (4 μM for complex I and 2 μM for complex II). Mitochondrial respiration was determined using a Clark-type oxygen electrode (Model 5331, YSI) with an oxygen monitor (Model 5300, YSI) and recorded with a potentiometric recorder (LKB 2210, LKB-Produkter AB, Sweden).

Mitochondrial ATP-synthase assay (complex V)

Enzymatic activity of ATPase in the mitochondrial inner membrane was measured by the method described in Taussky and Shorr (1953). The mitochondria samples were incubated at 37°C for 5 min in an enzyme reaction buffer (100 mM NaCl, 10 mM KCl, 50 mM Tris-acetate, pH 7.2, 0.1 mM EDTA, pH 8.0 and 3 mM MgCl2). The reaction was started by adding 3.33 mM ATP, and the mitochondria were further incubated at 37°C for 20 min. The reaction was stopped by adding ice-cold perchloric acid. The mixture was centrifuged at 8000 g for 10 min at 4°C, and the supernatant was incubated at room temperature (20°C) for 15 min after adding molybdate detection reagent. The absorbance was measured at 660 nm (Sudo et al., 2000).

Slice electrophysiology

Mice were deeply anesthetized with halothane, killed by decapitation and the brains dissected and immediately placed in oxygenated ice-cold low-Ca2+ and high-Mg2+ ACSF (artificial cerebrospinal fluid) containing 130 mM NaCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 5 mM MgCl2, 1 mM CaCl2 and 10 mM glucose. Coronal slices (350 μm) were cut and transferred to an incubating chamber containing ACSF (with 2 mM CaCl2 and 2 mM MgCl2) oxygenated with 95% O2, 5% CO2 (pH 7.2–7.4, 290–310 mOsm/l, 25±2°C). Following recovery, slices were placed on the stage of an upright microscope (Olympus BX51), submerged in continuously flowing ACSF (4 ml/min). All experiments were performed at room temperature. Whole-cell patch clamp recordings in voltage clamp mode were obtained from MSNs in the dorsolateral striatum visualized with the aid of infrared videomicroscopy (Cepeda et al., 1998). MSNs were identified by somatic size and typical basic membrane properties (input resistance, membrane capacitance and time constant). Series resistance was <25 MΩ. The patch pipette (4–6 MΩ) contained the following solution: 125 mM Cs-methanesulfonate, 3 mM KCl, 4 mM NaCl, 1 mM MgCl2, 5 mM MgATP, 9 mM EGTA, 8 mM Hepes, 1 mM GTP, 10 mM phosphocreatine and 0.1 mM leupeptin (pH 7.25–7.3 and osmolarity 280–290 mOsm/l). Passive membrane properties of MSNs were determined by applying a depolarizing step voltage command (10 mV) and using the membrane test function integrated in the pClamp8 software (Axon Instruments, Foster City, CA, U.S.A.). This function reports membrane capacitance (in pF), input resistance (in MΩ) and time constant (in ms). sEPSCs [spontaneous EPSCs (excitatory postsynaptic currents)] and sIPSCs [spontaneous IPSCs (inhibitory postsynaptic currents)] were first isolated electrophysiologically by holding the membrane at −70 mV and +10 mV respectively. After recording sIPSCs, bicuculline methiodide (BIC, 20 μM) was added to block GABAA (γ-aminobutyric acid type A) receptors and the membrane was stepped back to −70 mV to record sEPSCs without any possible contribution of GABAA receptors. mEPSCs (miniature EPSCs) were isolated by blocking Na+ channels using TTX (tetrodotoxin; 1 μM). The frequency of sEPSCs and mEPSCs was measured with MiniAnalysis software (Synaptosoft Inc, Fort Lee, NJ) using a threshold of 5 pA.

Acutely dissociated neuron preparation

Detailed procedures have been published (Flores-Hernandez et al., 2002; Andre et al., 2010). Coronal slices containing the dorsal striatum were dissected, placed in an oxygenated cell-stir chamber (Wheaton, Millville, NJ, U.S.A.) and enzymatically treated for 15–20 min with papain (0.5 mg/ml, Calbiochem) at 35°C in a Hepes-buffered HBSS (Hanks balanced salt solution; Sigma Chemical) supplemented with 1 mM pyruvic acid, 0.005 mM glutathione, 0.1 mM NG-nitro-l-arginine and 1 mM kynurenic acid. The tissue was rinsed with Hepes-buffered Na-isethionate solution containing 140 mM Na isethionate, 2 mM KCl, 2 mM MgCl2, 0.1 mM CaCl2, 23 mM glucose and 15 mM Hepes. Striatal slices were mechanically dissociated with fire-polished Pasteur pipettes. The cell suspension was then plated into a 35-mm Petri dish mounted on the stage of an upright fixed-stage microscope (Zeiss Axioscope, Thornwood, NY, U.S.A.) containing a Hepes-buffered salt solution. The internal solution consisted of 175 mM NMDG (N-methyl-d-glucamine), 40 mM Hepes, 2 mM MgCl2, 10 mM ethylene glycol-bis (β-aminoethyl ether)-N,N,N′,N′-tetra-acetic acid (EGTA), 12 mM phosphocreatine, 2 mM Na2 ATP, 0.2 mM Na2 GTP and 0.1 mM leupeptin (pH 7.25, 265–270 mOsm/l). The external solution consisted of 135 mM NaCl, 20 mM CsCl, 3 mM BaCl2, 2 mM CaCl2, 10 mM glucose, 10 mM Hepes and 0.0003 mM TTX. Drugs were applied through a pressure-driven fast perfusion system using application capillaries positioned a few hundred micrometres from the cell. A DC drive system controlled by an SF-77B perfusion system (Warner Instruments, Hamden, CT, U.S.A.) synchronized by pClamp changed solutions by altering the position of the capillary array. NMDA currents were evoked by applying the agonist (100 μM, 3 s duration every 10 s) while holding the cell at −70 mV in the absence or presence of Mg2+ (50 μM).

Statistics

Results are presented as means±S.E.M. and were analysed by unpaired Student's t test (two-tailed) between groups of biological relevance (e.g. young DE5 against young WT; old DE5 against old WT; young DE5 against old DE5; young WT against old WT). P<0.05 was considered significant, and actual P values are noted throughout the text.

RESULTS

Striatal volume is unchanged in mice expressing mhtt only in striatal neurons

Striatal volume loss occurs in HD patients and several pan-neuronal HD mouse models (Rosas et al., 2001; Slow et al., 2003; Chopra et al., 2007; Decressac et al., 2010). We examined possible age- and/or mhtt-dependent changes in striatal volume of DE5 and WT mice since a neuronal and volume loss could impact on conclusions drawn from numbers of degenerating neurons following equal doses of QA. Striatal volume was measured using the Cavalieri principle in all the animals used for QA injection. No significant striatal volume difference was observed between any pair of four cohorts of biological relevance (young DE5 = 17.15±1.13 mm3, young WT = 15.45±0.88 mm3, old DE5 = 14.50±0.96 mm3, old WT = 16.04±0.55 mm3) (Figure 1).

Figure 1
Striatal volume is unchanged in young (presymptomatic) and old (symptomatic) DE5 mice

Striatum of symptomatic DE5 mice is resistant to QA-induced excitotoxicity

Previous studies of excitotoxicity in HD mouse models utilized a wide range of QA doses (4–30 nmol) (Hansson et al., 1999, 2001; MacGibbon et al., 2002; Zeron et al., 2002; Jarabek et al., 2004; Graham et al., 2006; Graham et al., 2009). Within the same study, different doses may be used for younger against older mice due to age-related differences in sensitivity. The DE5 mouse is on a C57BL/6J background that is a relatively resistant strain to QA excitotoxicity (McLin et al., 2006). We first injected 4, 6, 15 and 30 nmol of QA into the striatum of young (2–2.5 months old) and old (>1 year old) C57BL/6J mice to identify a single dose that could be applied to both age groups without triggering a seizure, yet induce a measurable number of degenerating neurons. In young C57BL/6J mice, 4 and 6 nmol of QA did not yield a lesion but 30 nmol resulted in a lesion throughout the entire striatum, to which it is hard to make a comparison (results not shown). We therefore utilized a single dose of 15 nmol in all animals, enabling an accurate comparison across ages and genotypes (Figure 2).

Figure 2
DE5 symptomatic mice display increased resistance to excitotoxic insult

FJ-positive neurons were counted after intrastriatal injection of 15 nmol QA in young (presymptomatic) and old (symptomatic) DE5 mice and age-matched controls. There was no difference in the number of degenerating neurons between young DE5 and WT (young DE5 = 27010±3546, young WT = 19755±2563; P = 0.093) (Figure 3A), suggesting that non-cell-autonomous factors may lead to increased sensitivity to excitotoxicity observed at the presymptomatic stages in HD pan-cellular and pan-neuronal transgenic models (Hansson et al., 2001; Zeron et al., 2002; Graham et al., 2006, 2009). Importantly, although there was a trend to a greater number of degenerating neurons in young DE5 mice, it was statistically weakened as we increased the number of animals in both groups. Consistent with previous studies in rats and FVB mice (Finn et al., 1991; Cepeda et al., 1996; Graham et al., 2009), both DE5 and WT C57BL/6J mice show a dramatic age-dependent decrease in sensitivity to excitotoxic insult (Figure 3B). DE5 and WT mice exhibited 10-fold and 2-fold decreases in FJ-positive neurons (old DE5 = 2496±1535, old WT = 10195±3046) respectively compared with their younger counterparts (Figure 3B). Symptomatic DE5 mice showed greater resistance to excitotoxicity relative to presymptomatic DE5 mice (P<0.0001) (Figure 3B) and also relative to age-matched WT mice (P = 0.027) (Figure 3A), similar to data from pan-cellular HD models (Hansson et al., 1999, 2001; Graham et al., 2009). These results imply that striatal-specific expression of mhtt is sufficient to induce resistance to excitotoxicity at the symptomatic stage.

Figure 3
Quantification of FJC-positive degenerating neurons in presymptomatic (young), symptomatic (old) DE5 mice and age-matched controls after 15 nmol intrastriatal QA injection

Mitochondrial complex II respiration is dysregulated in the striatum of both pre- and symptomatic DE5 mice

In presymptomatic HD, MSN hypersensitivity to excitotoxicity may arise from an increased level of extracellular glutamate (non-cell-autonomous) and/or an imbalance between synaptic and extra-synaptic NMDARs (Milnerwood et al., 2010), mitochondrial dysfunction and altered energy metabolism in the presence of a normal extracellular level of glutamate (cell-autonomous) (Greene and Greenamyre, 1996). Thus, we examined whether mhtt cell-autonomously altered mitochondrial function by measuring striatal mitochondrial respiration using the polarographic method. These assays include (i) state 4 respiration with specific substrates for each complex (glutamate+malate, succinate and ascorbate+TMPD for complex I, II and IV respectively); (ii) state 3 respiration in the presence of ADP; and (iii) maximum rates of respiration by uncoupling mitochondria with FCCP. Complex I activities were not altered in the striatum of young and old DE5 mice relative to WT littermates (Figure 4A), but states 3 and 4 activities of complex II were significantly reduced in presymptomatic DE5 mice compared with their age-matched controls (Figure 4B). Not surprisingly, state 4 respiration of complex II was significantly reduced in old WT mice compared with young WT mice. Conversely, it was significantly enhanced in symptomatic DE5 mice compared with their age-matched controls (Figures 4B and 4E). Increases in state 3 and FCCP-induced maximum respiration were also present in symptomatic DE5 mice compared with presymptomatic DE5 mice (Figure 4B). No alterations in complex IV activities were observed in any of the mice (Figure 4C). ATP-synthase activities of complex V in symptomatic DE5 mice was found to be as efficient as in age-matched controls (Figure 4D). Thus, striatal-specific expression of mhtt affected complex II activities of mitochondrial respiration in an age-dependent manner but did not alter the activities of the other complexes.

Figure 4
Dysregulated mitochondrial complex II activities in the striatum of young and old DE5 mice

MSNs of symptomatic DE5 mice show an increase in input resistance and a decrease in NMDA current

To identify electrophysiological properties potentially associated with resistance to excitotoxicity in the striatum of symptomatic DE5 mice, we examined basic membrane properties and sEPSCs and sIPSCs in MSNs in slices from 18-month-old DE5 mice and their WT littermates (Figure 5A). There was a trend for reduced cell membrane capacitance, but the difference was not statistically significant. The only significant change in membrane properties was an increase in input resistance in the DE5 MSNs relative to WT control slices. This abnormality has been reported in many other HD mouse models, likely arising from a change in inwardly rectifying potassium channels (Cepeda et al., 2003, 2004; Ariano et al., 2005; Cummings et al., 2010). The frequency of sEPSCs and sIPSCs was not affected in DE5 mice. Thus, the transgene did not alter spontaneous synaptic inputs to MSNs, either excitatory inputs from cortex and thalamus or local inhibitory connections. Next, we recorded currents evoked by the application of 100 μM NMDA to acutely isolated MSNs from the mice (Figure 5B). This preparation is used to examine postsynaptic receptors at the cell somatic level. Peak current and current density (a measure that normalizes current by cell size) were reduced significantly, as also previously recorded in older R6/2, YAC128 and BAC103 mice (Graham et al., 2009; Joshi et al., 2009; Cepeda et al., 2010), whereas NMDA currents were increased in the 6-month-old striatal model of Gu et al. (2007). These changes would predict resistance to excitotoxicity and are therefore consistent with our data. A change in Mg2+ sensitivity sometimes occurs in MSNs in HD models (Starling et al., 2005; Gu et al., 2007); however, the transgene did not cause any change in Mg2+ sensitivity in the DE5 model.

Figure 5
Electrophysiological properties of MSNs in symptomatic DE5 mice

DISCUSSION

Excitotoxicity appears to be at least partly responsible for the degeneration of MSNs in HD (reviewed in Cowan and Raymond, 2006). Increased levels of glutamate and QA, endogenous NMDAR agonists, have been found in some studies in the striatum of early HD patients (Guidetti et al., 2004), and intrastriatal injections of QA have been used as a model of HD (DiFiglia, 1990; Guidetti et al., 2004; Sapko et al., 2006; Graham et al., 2009). Intrastriatal injections of QA and NMDA have been performed in several pan-cellular and pan-neuronal HD mouse models to determine the effects of mhtt on sensitivity to excitotoxicity. Presymptomatic YAC128 and R6/1 HD mice exhibited increased vulnerability to QA-induced excitotoxicity and enhanced NMDA responses; conversely, symptomatic, older mice became resistant to excitotoxic insult (Hansson et al., 2001; Zeron et al., 2002; Graham et al., 2006, 2009). Utilizing the HD mouse model that expresses mhtt in the MSNs of the striatum but not in the cortex or glia, we demonstrate that increased sensitivity to QA excitotoxicity in young, presymptomatic mice has a largely non-cell autonomous component and the increased resistance to excitotoxic insult observed in older symptomatic HD mice can be primarily attributed to cell-autonomous effects of mhtt. These results support the importance of disease-stage and cell-type-specific therapeutic approaches.

Existing data support the presence of enhanced NMDAR activity in early HD (Cepeda et al., 2001; Fernandes and Raymond, 2009). NMDAR-mediated, and specifically NR2B-dependent, excitotoxicity exacerbates striatal neuronal degeneration in an NR2B-overexpressing HD mouse model (Heng et al., 2009). NMDAR is linked to two opposing signalling pathways leading to either cell survival or death, depending on receptor localization (Hardingham and Bading, 2010; Levine et al., 2010). Mislocalization of NMDAR to the peri- and extra-synaptic membrane (non-PSD fraction) in presymptomatic YAC128 striatum leads to a loss of neuroprotective mechanisms, an increase in activity of cell death pathways and increased neurotoxicity (Okamoto et al., 2009; Milnerwood et al., 2010). In parallel, excitotoxicity triggered by overactivation of NR2B-containing NMDARs results in rapid dissociation of synaptic NMDARs from the postsynaptic scaffolding complex and downstream survival signalling (Gascon et al., 2008). Thus, one possible scenario is that excitotoxic damage occurs in striatal MSNs in the early stage of the disease by dysregulation of NMDAR-linked signalling pathways, which then leads to a cascade of age-dependent pathophysiological events.

The absence of the typical HD-related presymptomatic sensitivity to excitotoxicity in DE5 mice suggests that these early events are largely regulated in a non-cell-autonomous manner. These mechanisms may include an elevated glutamate level at the corticostriatal synapses due to excessive glutamate release from the cortex (Joshi et al., 2009), abnormal dopaminergic regulation of NMDAR expression (Snyder et al., 1998), decreased trophic support from the cortex and/or dysregulated glutamate uptake by astrocytes (Bradford et al., 2009, 2010; Faideau et al., 2010). The cell-specific expression of mhtt in the DE5 mouse would suggest that cortical and astrocytic functions are unaffected, unless there are secondary changes due to abnormal MSN function. The aetiology of increased extrasynaptic NMDAR in the presence of mhtt is unknown, but may be induced by glutamate spillover from excessive cortical release and/or reduced astrocytic uptake (Potier et al., 2010). Either way, if increased sensitivity to excitotoxicity in presymptomatic HD mice is determined by the synaptic/extrasynaptic NMDAR ratio, our results would imply that this intrinsic MSN abnormality may also be regulated in a non-cell-autonomous manner.

Mitochondrial dysfunction has been identified in HD patients and a variety of HD cell and mouse models (Stahl and Swanson, 1974; Brennan et al., 1985; Mann et al., 1990; Butterworth et al., 1998; Sawa et al., 1999; Tabrizi et al., 2000; Panov et al., 2002; Bae et al., 2005; Benchoua et al., 2006; Solans et al., 2006; Fukui and Moraes, 2007). While no complex I deficiency was found in the frontal and parietal cortices or the cerebellum of HD-patient brains (Browne et al., 1997), other clinical studies showed down-regulated mRNA levels of 12 subunits of complex I in HD brains (Weydt et al., 2006) and decreased complex I activity in platelets and muscle tissues of HD patients (Parker et al., 1990; Arenas et al., 1998). A significant reduction in complexes II and III activity was reported in both HD caudate and putamen, and decreased complex IV activity was also observed in HD putamen (Gu et al., 1996; Browne et al., 1997).

The application of 3-NP (3-nitropropionic acid), an irreversible complex II inhibitor, causes striatal cell loss in vivo in rodents, which is ameliorated by decortication or an NMDAR antagonist (Beal et al., 1993). In HD, mitochondrial dysfunction may arise from intrinsic abnormalities of transcription, including of PGC-1α (peroxisome-proliferator-activated receptor γ co-activator-1α), Ca2+ overload, NMDAR dysfunction and/or abnormal dopaminergic activity. In primary striatal cultures, dopamine regulates mitochondrial complex II catalytic activity and determines vulnerability of mhtt-expressing neurons to cell death (Benchoua et al., 2008). Our results imply that cell-autonomous abnormalities are sufficient to cause mitochondrial complex II dysfunction in the absence of a decrease in PGC-1α (Thomas et al., 2011), but that this level of decrease in complex II function in presymptomatic mice is not sufficient to cause enhanced sensitivity to excitotoxicity.

As noted above, our results suggest that resistance to excitotoxicity in symptomatic HD mice may be largely mediated by cell-autonomous mechanisms. Aging causes decreased NMDA and AMPA currents and reduced cortical input in MSNs, providing a natural protection from excitotoxicity (Cepeda et al., 1996, 2010; Graham et al., 2009). Indeed, the striatum becomes increasingly resistant to QA excitotoxicity in FVB and C57BL/6J mice (Hansson et al., 2001; Zeron et al., 2002; Graham et al., 2006, 2009). We also showed in vivo that striatal neuron-specific expression of mhtt is sufficient to cause an even greater reduction in NMDA current in symptomatic DE5 mice than in non-transgenic aged mice, implying that MSNs expressing mhtt may undergo further cell-autonomous disruption of NMDARs and downstream signalling in an age-dependent manner. It is hypothesized that with HD disease progression, there is a gradual corticostriatal disconnection (Cepeda et al., 2007; Papadia and Hardingham, 2007; Leveille et al., 2008; Joshi et al., 2009), which could contribute to the suppressed excitotoxic response in symptomatic HD mice since induction of an in vivo excitotoxic lesion requires the integrity of corticostriatal pathways (McGeer et al., 1978). Our electrophysiological data did not show any decrease of EPSCs in the DE5 mice suggesting that glutamate synaptic transmission is not altered in mice expressing mhtt in MSNs only. IPSCs were not changed either, in contrast to other studies showing an increase of GABA synaptic activity in several models of HD (Cepeda et al., 2004). This indicates that the absence of cortical mhtt expression prevents abnormalities of corticostriatal synaptic function, and thus no true corticostriatal disconnection may occur in symptomatic DE5 mice. In contrast, MSNs showed alterations in some membrane properties (increased input resistance), and postsynaptic currents similar to pan-neuronal models of HD, suggesting those changes are cell-autonomous and might be sufficient to induce motor dysfunction (Brown et al., 2008).

Even without any alteration or loss of glutamatergic input, abnormal postsynaptic receptors are likely sufficient to affect the physiology and excitability of MSNs. Further work is required to determine the number, composition and location of NMDARs in DE5 MSNs. In addition, the enhanced mitochondrial complex II respiration observed in symptomatic DE5 mice may contribute to the paradoxical cell-autonomous resistance to QA-induced excitotoxicity. Sustained overexpression of mitochondrial complex II protein subunits in cultured striatal neurons expressing htt-N171-82Q restores complex II activity and suppresses mitochondrial dysfunction and neuronal cell death (Benchoua et al., 2008). The increased complex II activity in the symptomatic DE5 striatum may be due to up-regulated PGC-1α expression (Thomas et al., 2011), which protects against mitochondrial dysfunction and mhtt-induced striatal toxicity by controlling many mitochondrial genes (Cui et al., 2006). In contrast, the striatum of symptomatic HD N171-82Q mice and HD patients showed decreased PGC-1α and its downstream targets (Cui et al., 2006; Weydt et al., 2006). PGC-1α is regulated by CREB (cAMP-response-element-binding protein), deactivation of which occurs by extrasynaptic NMDAR stimulation. Thus, imbalance between synaptic and extrasynaptic NMDAR signalling could also contribute to the induction of excitotoxicity via mitochondrial dysfunction. Again, however, in view of opposite effects on PGC-1α level in pan-neuronal and DE5 mice, changes in this molecule alone are unlikely to account for the acquired resistance to excitotoxicity.

ACKNOWLEDGEMENTS

We thank Dr Terry A. Krulwich and Dr David B. Hicks for use of the oxygen electrode system, Dr Merina T. Varghese for assistance with the respiration assay, Loren Khan-Vaughan and Justine Bonet for assistance with mouse colony management, and Dr James Schmeidler for advice on the statistical analysis (all from Mount Sinai School of Medicine).

Footnotes

This work was supported in part by the National Institutes of Health [Grant NS059936 to M.E.E. and NS041574 to M.S.L.]; the Cure Huntington's Disease Initiative (separately to M.E.E. and M.S.L.); and the Hereditary Disease Foundation (to M.S.L.).

REFERENCES

  • Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997;389:856–860. [PubMed]
  • Andre VM, Cepeda C, Cummings DM, Jocoy EL, Fisher YE, William Yang X, Levine MS. Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. Eur J Neurosci. 2010;31:14–28. [PubMed]
  • Arenas J, Campos Y, Ribacoba R, Martin MA, Rubio JC, Ablanedo P, Cabello A. Complex I defect in muscle from patients with Huntington's disease. Ann Neurol. 1998;43:397–400. [PubMed]
  • Ariano MA, Cepeda C, Calvert CR, Flores-Hernandez J, Hernandez-Echeagaray E, Klapstein GJ, Chandler SH, Aronin N, DiFiglia M, Levine MS. Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol. 2005;93:2565–2574. [PubMed]
  • Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, Hayward SD, Moran TH, Montell C, Ross CA, Snyder SH, Sawa A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron. 2005;47:29–41. [PubMed]
  • Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 1993;13:4181–4192. [PubMed]
  • Benchoua A, Trioulier Y, Diguet E, Malgorn C, Gaillard MC, Dufour N, Elalouf JM, Krajewski S, Hantraye P, Deglon N, Brouillet E. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum Mol Genet. 2008;17:1446–1456. [PubMed]
  • Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, Saudou F, Elalouf JM, Hirsch E, Hantraye P, Deglon N, Brouillet E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell. 2006;17:1652–1663. [PMC free article] [PubMed]
  • Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA. 2009;106:22480–22485. [PubMed]
  • Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S, Li XJ. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem. 2010;285:10653–10661. [PubMed]
  • Brennan WA Jr, Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem. 1985;44:1948–1950. [PubMed]
  • Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA. 1995;92:7105–7109. [PubMed]
  • Brown TB, Bogush AI, Ehrlich ME. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Hum Mol Genet. 2008;17:3095–3104. [PMC free article] [PubMed]
  • Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997;41:646–653. [PubMed]
  • Butterworth NJ, Williams L, Bullock JY, Love DR, Faull RL, Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience. 1998;87:49–53. [PubMed]
  • Cepeda C, Li Z, Levine MS. Aging reduces neostriatal responsiveness to N-methyl-d-aspartate and dopamine: an in vitro electrophysiological study. Neuroscience. 1996;73:733–750. [PubMed]
  • Cepeda C, Colwell CS, Itri JN, Chandler SH, Levine MS. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol. 1998;79:82–94. [PubMed]
  • Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS. The corticostriatal pathway in Huntington's disease. Prog Neurobiol. 2007;81:253–271. [PMC free article] [PubMed]
  • Cepeda C, Cummings DM, Andre VM, Holley SM, Levine MS. Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro. 2010;2:e00033. [PMC free article] [PubMed]
  • Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt BR, Hayden MR, Levine MS. NMDA receptor function in mouse models of Huntington disease. J Neurosci Res. 2001;66:525–539. [PubMed]
  • Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci. 2003;23:961–969. [PubMed]
  • Cepeda C, Starling AJ, Wu N, Nguyen OK, Uzgil B, Soda T, Andre VM, Ariano MA, Levine MS. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res. 2004;78:855–867. [PubMed]
  • Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci USA. 2007;104:16685–16689. [PubMed]
  • Collingridge GL, Lester RA. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev. 1989;41:143–210. [PubMed]
  • Cowan CM, Raymond LA. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol. 2006;75:25–71. [PubMed]
  • Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262:689–695. [PubMed]
  • Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127:59–69. [PubMed]
  • Cummings DM, Cepeda C, Levine MS. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro. 2010;2:e00036. [PMC free article] [PubMed]
  • Decressac M, Wright B, Tyers P, Gaillard A, Barker RA. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp Neurol. 2010;226:24–32. [PubMed]
  • DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 1990;13:286–289. [PubMed]
  • Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, Ge P, Vonsattel JP, Gusella JF, Joyner AL. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. 1995;269:407–410. [PubMed]
  • Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P, Deglon N, Ferrante RJ, Bonvento G. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet. 2010;19:3053–3067. [PMC free article] [PubMed]
  • Fan MM, Raymond LA. N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol. 2007;81:272–293. [PubMed]
  • Fernandes HB, Raymond LA. NMDA Receptors and Huntington's Disease. In: Van Dongen AM, editor. In Biology of the NMDA Receptor. 2009. pp. pp. 17–40. CRC Press, Boca Raton, FL.
  • Finn SF, Hyman BT, Storey E, Miller JM, Beal MF. Effects of aging on quinolinic acid lesions in rat striatum. Brain Res. 1991;562:276–280. [PubMed]
  • Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, Calvert CR, Jokel ES, Fienberg AA, Greengard P, Levine MS. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol. 2002;88:3010–3020. [PubMed]
  • Fukui H, Moraes CT. Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates. Hum Mol Genet. 2007;16:783–797. [PubMed]
  • Gascon S, Sobrado M, Roda JM, Rodriguez-Pena A, Diaz-Guerra M. Excitotoxicity and focal cerebral ischemia induce truncation of the NR2A and NR2B subunits of the NMDA receptor and cleavage of the scaffolding protein PSD-95. Mol Psychiatry. 2008;13:99–114. [PubMed]
  • Godin JD, Colombo K, Molina-Calavita M, Keryer G, Zala D, Charrin BC, Dietrich P, Volvert ML, Guillemot F, Dragatsis I, Bellaiche Y, Saudou F, Nguyen L, Humbert S. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron. 2010;67:392–406. [PubMed]
  • Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, Andre VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci. 2009;29:2193–2204. [PMC free article] [PubMed]
  • Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, Raymond LA, Nicholson DW, Hayden MR. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125:1179–1191. [PubMed]
  • Greene JG, Greenamyre JT. Bioenergetics and glutamate excitotoxicity. Prog Neurobiol. 1996;48:613–634. [PubMed]
  • Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol. 1996;39:385–389. [PubMed]
  • Gu X, Andre VM, Cepeda C, Li SH, Li XJ, Levine MS, Yang XW. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener. 2007;2:8. [PMC free article] [PubMed]
  • Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis. 2004;17:455–461. [PubMed]
  • Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987;147:229–263. [PubMed]
  • Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA. 1999;96:8727–8732. [PubMed]
  • Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF, Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene. Eur J Neurosci. 2001;14:1492–1504. [PubMed]
  • Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans. 2009;37:1147–1160. [PMC free article] [PubMed]
  • Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682–696. [PMC free article] [PubMed]
  • Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci. 2009;29:3200–3205. [PubMed]
  • Jarabek BR, Yasuda RP, Wolfe BB. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain. 2004;127:505–516. [PubMed]
  • Joshi PR, Wu NP, Andre VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci. 2009;29:2414–2427. [PMC free article] [PubMed]
  • Leveille F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008;22:4258–4271. [PubMed]
  • Levine MS, Cepeda C, Andre VM. Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease. Neuron. 2010;65:145–147. [PMC free article] [PubMed]
  • Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol. 1957;58:193–201. [PubMed]
  • MacDonald ME, Duyao M, Calzonetti T, Auerbach A, Ryan A, Barnes G, White JK, Auerbach W, Vonsattel JP, Gusella JF, Joyner AL. Targeted inactivation of the mouse Huntington's disease gene homolog Hdh. Cold Spring Harb Symp Quant Biol. 1996;61:627–638. [PubMed]
  • MacGibbon GA, Hamilton LC, Crocker SF, Costain WJ, Murphy KM, Robertson HA, Denovan-Wright EM. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice. J Neurosci Res. 2002;67:372–378. [PubMed]
  • Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, Schapira AH. Mitochondrial function and parental sex effect in Huntington's disease. Lancet. 1990;336:749. [PubMed]
  • McGeer EG, McGeer PL, Singh K. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract. Brain Res. 1978;139:381–383. [PubMed]
  • McLin JP, Thompson LM, Steward O. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. Eur J Neurosci. 2006;24:3134–3140. [PubMed]
  • Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 2010;65:178–190. [PubMed]
  • Nicholls DG. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim Biophys Acta. 2009;1787:1416–1424. [PMC free article] [PubMed]
  • Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2009;15:1407–1413. [PMC free article] [PubMed]
  • Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci. 2002;5:731–736. [PubMed]
  • Papadia S, Hardingham GE. The dichotomy of NMDA receptor signaling. Neuroscientist. 2007;13:572–579. [PMC free article] [PubMed]
  • Parker Jr WD, Boyson SJ, Luder AS, Parks JK. Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology. 1990;40:1231–1234. [PubMed]
  • Potier B, Billard JM, Riviere S, Sinet PM, Denis I, Champeil-Potokar G, Grintal B, Jouvenceau A, Kollen M, Dutar P. Reduction in glutamate uptake is associated with extrasynaptic NMDA and metabotropic glutamate receptor activation at the hippocampal CA1 synapse of aged rats. Aging Cell. 2010;9:722–735. [PubMed]
  • Rosas HD, Goodman J, Chen YI, Jenkins BG, Kennedy DN, Makris N, Patti M, Seidman LJ, Beal MF, Koroshetz WJ. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology. 2001;57:1025–1028. [PubMed]
  • Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol. 2006;197:31–40. [PubMed]
  • Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr, Greenamyre JT, Snyder SH, Ross CA. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999;5:1194–1198. [PubMed]
  • Schmued LC, Albertson C, Slikker Jr W. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 1997;751:37–46. [PubMed]
  • Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12:1555–1567. [PubMed]
  • Snyder GL, Fienberg AA, Huganir RL, Greengard P. A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci. 1998;18:10297–10303. [PubMed]
  • Solans A, Zambrano A, Rodriguez M, Barrientos A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet. 2006;15:3063–3081. [PubMed]
  • Stahl WL, Swanson PD. Biochemical abnormalities in Huntington's chorea brains. Neurology. 1974;24:813–819. [PubMed]
  • Starling AJ, Andre VM, Cepeda C, de Lima M, Chandler SH, Levine MS. Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res. 2005;82:377–386. [PubMed]
  • Sudo J, Terui J, Iwase H, Kakuno K. Assay of ATPase and Na,K-ATPase activity using high-performance liquid chromatographic determination of ADP derived from ATP. J Chromatogr B Biomed Sci Appl. 2000;744:19–23. [PubMed]
  • Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000;47:80–86. [PubMed]
  • Taussky HH, Shorr E. A microcolorimetric method for the determination of inorganic phosphorus. J Biol Chem. 1953;202:675–685. [PubMed]
  • Thomas EA, Coppola G, Tang B, Kuhn A, Kim S, Geschwind DH, Brown TB, Luthi-Carter R, Ehrlich ME. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum Mol Genet. 2011;20:1049–1060. [PMC free article] [PubMed]
  • Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson Jr EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985;44:559–577. [PubMed]
  • Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 2006;4:349–362. [PubMed]
  • Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 2002;33:849–860. [PubMed]
  • Zhou M, Baudry M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J Neurosci. 2006;26:2956–2963. [PubMed]

Articles from ASN NEURO are provided here courtesy of SAGE Publications